Proteasomes generate spliced epitopes by two different mechanisms and as efficiently as non-spliced epitopes

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Ebstein, F ^a   Textoris Taube, K ^a   Keller, C ^a   Golnik, R ^a   Vigneron, N ^b   Van Den Eynde, B J ^b   Schuler Thurner, B ^c   Schadendorf, D ^d,g   Lorenz, F K M ^e   Uckert, W ^e,f   Urban, S ^a   Lehmann, A ^a   Albrecht Koepke, N ^a   Janek, K ^a   Henklein, P ^a   Niewienda, A ^a   Kloetzel, P M ^a   Mishto, M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^f HUMBOLDT UNIVERSITY   (Germany)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; EPITOPE; GAMMA INTERFERON; MELANOCYTE PROTEIN PMEL 17; PEPTIDE; PROTEASOME; TUMOR ANTIGEN;

ALGORITHM; ALTERNATIVE RNA SPLICING; ANTIGEN PRESENTATION; CASE CONTROL STUDY; CATALYSIS; CD8+ T LYMPHOCYTE; CHEMISTRY; CYTOLOGY; HELA CELL LINE; HUMAN; IMMUNOLOGY; MELANOCYTE; MELANOMA; METABOLISM; PROBABILITY; TUMOR CELL LINE;

ALGORITHMS; ALTERNATIVE SPLICING; ANTIGEN PRESENTATION; ANTIGENS; ANTIGENS, NEOPLASM; CASE-CONTROL STUDIES; CATALYSIS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; EPITOPES; EPITOPES, T-LYMPHOCYTE; GP100 MELANOMA ANTIGEN; HELA CELLS; HUMANS; INTERFERON-GAMMA; MELANOCYTES; MELANOMA; PEPTIDES; PROBABILITY; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 84963682507     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep24032     Document Type: Article

References (35)

1. Dahlmann, B., Ruppert, T., Kuehn, L., Merforth, S. & Kloetzel, P. M. Different proteasome subtypes in a single tissue exhibit different enzymatic properties. J Mol Biol 303, 643-653 (2000)
2. Guillaume, B. et al. Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules. Proc Natl Acad Sci USA 107, 18599-18604 (2010)
3. Groll, M. et al. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 386, 463-471 (1997)
4. Navon, A. & Ciechanover, A. The 26 S proteasome: from basic mechanisms to drug targeting. J Biol Chem 284, 33713-33718 (2009)
5. Kloetzel, P. M. Antigen processing by the proteasome. Nat Rev Mol Cell Biol 2, 179-187 (2001)
6. Liepe, J. et al. Quantitative time-resolved analysis reveals intricate, differential regulation of standard- and immuno-proteasomes. Elife doi: 10.7554/eLife.07545 (2015)
7. Huber, E. M. et al. Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell 148, 727-738 (2012)
8. Arciniega, M., Beck, P., Lange, O. F., Groll, M. & Huber, R. Differential global structural changes in the core particle of yeast and mouse proteasome induced by ligand binding. Proc Natl Acad Sci USA 111, 9479-9484 (2014)
9. Mishto, M. et al. Proteasome isoforms exhibit only quantitative differences in cleavage and epitope generation. Eur J Immunol 44, 3508-3521 (2014)
10. Vigneron, N. & Van den Eynde, B. J. Proteasome subtypes and the processing of tumor antigens: increasing antigenic diversity. Curr Opin Immunol 24, 84-91 (2011)
11. Warren, E. H. et al. An antigen produced by splicing of noncontiguous peptides in the reverse order. Science 313, 1444-1447 (2006)
12. Vigneron, N. et al. An antigenic peptide produced by peptide splicing in the proteasome. Science 304, 587-590 (2004)
13. Dalet, A., Vigneron, N., Stroobant, V., Hanada, K. & Van den Eynde, B. J. Splicing of distant Peptide fragments occurs in the proteasome by transpeptidation and produces the spliced antigenic peptide derived from fibroblast growth factor-5. J Immunol 184, 3016-3024 (2010)
14. Mishto, M. et al. Driving Forces of Proteasome-catalyzed Peptide Splicing in Yeast and Humans. Mol Cell Proteomics 11, 1008-1023 (2012)
15. Borissenko, L. & Groll, M. Diversity of proteasomal missions: fine tuning of the immune response. Biol Chem 388, 947-955 (2007)
16. Berkers, C. R., de Jong, A., Ovaa, H. & Rodenko, B. Transpeptidation and reverse proteolysis and their consequences for immunity. Int J Biochem Cell Biol 41, 66-71 (2009)
17. Somalinga, B. R. & Roy, R. P. Volume exclusion effect as a driving force for reverse proteolysis. Implications for polypeptide assemblage in a macromolecular crowded milieu. J Biol Chem 277, 43253-43261 (2002)
18. Michaux, A. et al. A Spliced Antigenic Peptide Comprising a Single Spliced Amino Acid is Produced in the Proteasome by Reverse Splicing of a Longer Peptide Fragment followed by Trimming. J Immunol 192, 1962-1971 (2014)
19. Hanada, K., Yewdell, J. W. & Yang, J. C. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 427, 252-256 (2004)
20. Dalet, A. et al. An antigenic peptide produced by reverse splicing and double asparagine deamidation. Proc Natl Acad Sci USA 108, 323-331 (2011)
21. Robbins, P. F. et al. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res 54, 3124-3126 (1994)
22. Bonnet, D., Warren, E. H., Greenberg, P. D., Dick, J. E. & Riddell, S. R. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci USA 96, 8639-8644 (1999)
23. Liepe, J. et al. The 20S Proteasome Splicing Activity Discovered by SpliceMet. Plos Computational Biology 6, e1000830 (2010)
24. Peters, B. & Sette, A. Integrating epitope data into the emerging web of biomedical knowledge resources. Nat Rev Immunol 7, 485-490 (2007)
25. Bellavista, E. et al. Immunoproteasome in cancer and neuropathologies: a new therapeutic target? Curr Pharm Des 19, 702-718 (2013)
26. Jager, E. et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 97, 12198-12203 (2000)
27. Saska, I. & Craik, D. J. Protease-catalysed protein splicing: a new post-translational modification? Trends Biochem Sci 33, 363-368 (2008)
28. Cresswell, P. Antigen processing and presentation. Immunol Rev 207, 5-7 (2005)
29. Mishto, M. et al. Immunoproteasome LMP2 60HH variant alters MBP epitope generation and reduces the risk to develop multiple sclerosis in Italian female population. Plos One 5, e9287 (2010)
30. Mishto, M. et al. A structural model of 20S immunoproteasomes: effect of LMP2 codon 60 polymorphism on expression, activity, intracellular localisation and insight into the regulatory mechanisms. Biol Chem 387, 417-429 (2006)
31. Ebstein, F., Lehmann, A. & Kloetzel, P. M. The FAT10- and ubiquitin-dependent degradation machineries exhibit common and distinct requirements for MHC class I antigen presentation. Cell Mol Life Sci 69, 2443-2454 (2012)
32. Fonteneau, J. F. et al. Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells. J Immunol Methods 258, 111-126 (2001)
33. Sommermeyer, D. et al. Designer T cells by T cell receptor replacement. Eur J Immunol 36, 3052-3059 (2006)
34. Morgan, R. A. et al. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol 171, 3287-3295 (2003)
35. Grant, E. et al. Nucleoprotein of influenza A virus is a major target of immunodominant CD8+ T-cell responses. Immunol Cell Biol 91, 184-194 (2013